Overview: Cytomegalovirus and the Herpesviruses in Transplantation: Overview: The Herpesviruses, American Journal of Transplantation, vol.13, issue.s3, pp.1-8, 2013. ,
Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection, Reviews in Medical Virology, vol.20, issue.4, pp.202-215, 2010. ,
Infections à cytomégalovirus. EMC -Maladies infectieuses, vol.6, pp.1-19, 2009. ,
Relationship between Toll-Like Receptor 2 Polymorphism and Cytomegalovirus Disease after Liver Transplantation, Clinical Infectious Diseases, vol.44, issue.10, pp.1315-1335, 2007. ,
The Number of Activating KIR Genes Inversely Correlates with the Rate of CMV Infection/Reactivation in Kidney Transplant Recipients, American Journal of Transplantation, vol.8, issue.6, pp.1312-1319, 2008. ,
Cytomegalovirus Replication Kinetics in Solid Organ Transplant Recipients Managed by Preemptive Therapy: CMV and Preemptive Antiviral Therapy, American Journal of Transplantation, vol.12, issue.9, pp.2457-64, 2012. ,
Major Expansion of gd T Lymphocytes following Cytomegalovirus Infection in Kidney Allograft Recipients, The Journal of Infectious Disease, 1999. ,
Surveillance of ?? T Cells Predicts Cytomegalovirus Infection Resolution in Kidney Transplants, Journal of American Society of Nephrology, vol.27, issue.2, pp.637-682, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01288893
Infection in Solid-Organ Transplant Recipients, The New England Journal of Medicine, vol.14, 2007. ,
Easier Control of Late-Onset Cytomegalovirus Disease Following Universal Prophylaxis Through an Early Antiviral Immune Response in Donor-Positive, Recipient-Negative Kidney Transplants, Am J Transplant, vol.16, issue.8, pp.2384-94, 2016. ,
,
, Interleukin 2 receptor antagonists for kidney transplant recipients, Cochrane Database of Systematic Reviews, 2010.
Delayed-Onset Cytomegalovirus Disease Coded During Hospital Readmission After Kidney Transplantation: Transplantation, vol.98, pp.187-94, 2014. ,
Impact of Antiviral Preventive Strategies on the Incidence and Outcomes of Cytomegalovirus Disease in Solid Organ Transplant Recipients: Impact of CMV Prevention, American Journal of Transplantation, vol.13, issue.9, pp.2402-2412, 2013. ,
Cytomegalovirus infection in transplant recipients, Clinics, vol.70, issue.7, pp.515-538, 2015. ,
Cytomegalovirus Infections in Solid Organ Transplantation: A Review, Infection & Chemotherapy, vol.45, issue.3, p.260, 2013. ,
Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1. Snydman DR, éditeur, Clin Infect Dis. 1 janv, vol.64, issue.1, pp.87-91, 2017. ,
The 'Indirect' Effects of Cytomegalovirus Infection, American Journal of Transplantation, vol.9, issue.11, pp.2453-2461, 2009. ,
The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ, Transplantation: Transplantation, vol.102, issue.6, pp.900-931, 2018. ,
The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients, American Journal of Transplantation. mai, vol.10, issue.5, pp.1228-1265, 2010. ,
Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: 1-Year Results of a Randomized Clinical Trial, Transplantation. janv, vol.93, issue.1, pp.61-69, 2012. ,
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation, Journal of American Society of Nephrology, vol.29, issue.7, pp.1979-91, 2018. ,
CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials, Clinical Journal of American Society of Nephrology, vol.12, issue.8, pp.1321-1357, 2017. ,
The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial, Transpl Infect Dis, vol.20, issue.4, pp.1345-56, 2018. ,
Improvement in Long-Term Renal Graft Survival due to CMV Prophylaxis with Oral Ganciclovir: Results of a Randomized Clinical Trial, American Journal of Transplantation, vol.8, issue.5, pp.975-983, 2008. ,
Complications infectieuses de la transplantation rénale. EMC Néphrologie, 2020. ,
Antiviral Drug Resistance of Human Cytomegalovirus, Clinical Microbiology Reviews, vol.23, issue.4, pp.689-712, 2010. ,
Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients, American Journal of Transplantation, vol.7, issue.9, pp.2106-2113, 2007. ,
Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients, American Journal of Transplantation, vol.9, issue.5, pp.1205-1213, 2009. ,
Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir, Antiviral Therapy, 2009. ,
Effects of the Intensity of Immunosuppressive Therapy on Outcome of Treatment for CMV Disease in Organ Transplant Recipients, American Journal of Transplantation, vol.10, issue.8, pp.1881-1888, 2010. ,
Overview: Cytomegalovirus and the Herpesviruses in Transplantation, American Journal of Transplantation, vol.13, issue.s3, pp.1-8, 2013. ,
Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients, American Journal of Transplantation, vol.7, issue.9, pp.2106-2113, 2007. ,
The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation, Transplantation, vol.102, issue.6, pp.900-931, 2018. ,
Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials, Clinical Infectious Diseases, vol.68, issue.8, pp.1420-1426, 2018. ,
Analysis and Characterization of Antiviral Drug?Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients, The Journal of Infectious Diseases, vol.186, issue.6, pp.760-768, 2002. ,
Analysis and Characterization of Antiviral Drug?Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients, The Journal of Infectious Diseases, vol.186, issue.6, pp.760-768, 2002. ,
Novel DNA polymerase mutations conferring cytomegalovirus resistance: Input of BAC-recombinant phenotyping and 3D model, Antiviral Research, vol.98, issue.1, pp.130-134, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01101111
Cytomegalovirus infections in heart and heart-lung transplant recipients, Journal of Antimicrobial Chemotherapy, vol.23, issue.suppl E, pp.49-60, 1989. ,
,
, Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir, Antiviral Therapy, 2009.
High Incidence of Anticytomegalovirus Drug Resistance Among D+R? Kidney Transplant Recipients Receiving Preemptive Therapy: Preemptive Therapy and Drug-Resistant CMV, American Journal of Transplantation, vol.12, issue.1, pp.202-211, 2012. ,
High Incidence of Ganciclovir-Resistant Cytomegalovirus Infection among Lung Transplant Recipients Receiving Preemptive Therapy, Journal of Infectious Disease, vol.185, issue.1, pp.20-27, 2002. ,
Antiviral Drug Resistance of Human Cytomegalovirus, Clinical Microbiology Reviews, vol.23, issue.4, pp.689-712, 2010. ,
The Time Course of Development and Impact From Viral Resistance Against Ganciclovir in Cytomegalovirus Infection: Resistance Against Ganciclovir in CMV, American Journal of Transplantation, vol.13, issue.2, pp.458-66, 2013. ,
Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients, Clinical Infectious Diseases, vol.65, issue.1, pp.57-63, 2017. ,
Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy, Proceedings of the National Academy of Sciences, vol.97, issue.14, pp.8039-8083, 2000. ,
Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis, Journal of Clinical Virology, vol.53, issue.3, pp.208-221, 2012. ,
Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection: Transplantation, vol.100, pp.74-80, 2016. ,
Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients, American Journal of Transplantation, vol.9, issue.5, pp.1205-1218, 2009. ,
,
, Whole blood real-time quantitative PCR for cytomegalovirus infection follow-up in transplant recipients, Journal of Clinical Virology, vol.36, issue.1, pp.72-77, 2006.
Prediction of Cytomegalovirus (CMV) Plasma Load from Evaluation of CMV Whole-Blood Load in Samples from Renal Transplant Recipients, Journal of Clinical Microbiology, vol.46, issue.2, pp.493-501, 2008. ,
Approach to drug-resistant cytomegalovirus in transplant recipients: Current Opinion in Infectious Diseases, vol.28, pp.293-302, 2015. ,
Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1. Snydman DR, éditeur, Clin Infect Dis, vol.64, issue.1, pp.87-91, 2017. ,
Easier Control of Late-Onset Cytomegalovirus Disease Following Universal Prophylaxis Through an Early Antiviral Immune Response in Donor-Positive, Recipient-Negative Kidney Transplants, Am J Transplant, vol.16, issue.8, pp.2384-94, 2016. ,
Recurrence of CMV Infection and the Effect of, Prolonged Antivirals in Organ Transplant Recipients: Transplantation, vol.101, issue.6, pp.1449-54, 2017. ,
Surveillance of ?? T Cells Predicts Cytomegalovirus Infection Resolution in Kidney Transplants, Journal of American Society of Nephrology, vol.27, issue.2, pp.637-682, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01288893
An Interventional Study Using Cell-Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation, Am J Transplant, vol.17, issue.9, pp.2468-73, 2017. ,
Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy, Transpl Int, vol.27, issue.10, pp.1060-1068, 2014. ,
,
, Absolute Lymphocyte Count: A Predictor of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients, Clinical Infectious Diseases, vol.67, issue.9, pp.1395-402, 2018.
Clinical Predictors of Relapse after Treatment of Primary Gastrointestinal Cytomegalovirus Disease in Solid Organ Transplant Recipients: Predictors of Relapse of GI CMV Disease after SOT, American Journal of Transplantation, vol.10, issue.1, pp.157-61, 2010. ,
The risk of cytomegalovirus recurrence after kidney transplantation: Recurrent CMV after kidney transplantation, Transplant International, vol.24, issue.12, pp.1170-1178, 2011. ,
Role of Secondary Prophylaxis With Valganciclovir in the Prevention of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients, Clinical Infectious Diseases, vol.65, issue.12, pp.109-165, 2000. ,
, Day 21 ciclosporin blood concentration (ng/ml, median, vol.140, pp.110-170
, Baseline Lymphocyte count (G/l, median, IQR)
, Abbreviations: Antibody Mediated Rejection (ABMR
, Antithymocyte Globulin (ATG
, Cytomegalovirus (CMV
, Donor (D)
, estimated Glomerular Filtration Rate (eGFR)
, T Cell Mediation Rejection (TCMR)
, Multivariate analysis was performed for all covariates in case of a p-value<0.25 observed in the univariate analysis (in bold). We decided, for clarity, to show only significant factors in multivariate analysis
, Serment d'Hippocrate
, Au moment d'être admis à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité
, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux
, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions
, J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité
, Même sous la contrainte, je ne ferai pas usage de mes connaissances contre les lois de l'humanité
, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences
, Je donnerai mes soins à l'indigent et à quiconque me les demandera
, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire
, Admis dans l'intimité des personnes, je tairai les secrets qui me seront confiés
, Reçu à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira
, Je préserverai l'indépendance nécessaire à l'accomplissement de ma mission
, Je n'entreprendrai rien qui dépasse mes compétences
, Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés
, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité
, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses, que je sois déshonoré et méprisé si j'y manque. » Characteristics and time course of CMV infections leading to